Skip to Primary Navigation

Skip to main content

CVS Health resolves $37.76m settlement with DOJ for over-dispensing insulin pens to patients

CVS / Pharmacy outdoor signage in parking lot with car in foreground.
Photo: Justin Sullivan/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

CVS admitted to dispensing more insulin to patients than needed and receiving ineligible reimbursements.

CVS Health will pay $37.76m to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid, and other government healthcare programs.

The settlement resolves charges that CVS Pharmacy, a key subsidiary of CVS Health, violated the federal False Claims Act (FCA) between

, , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience